cilest 35microgram/250microgram tablets
janssen-cilag ltd - norgestimate; ethinylestradiol - oral tablet - 250microgram ; 35microgram
durogesic dtrans 25micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 25microgram/1hour
durogesic dtrans 50micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 50microgram/1hour
durogesic dtrans 75micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 75microgram/1hour
durogesic dtrans 100micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 100microgram/1hour
durogesic dtrans 12micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 12microgram/1hour
concerta xl 36 mg prolonged-release tablets
janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 36 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient
concerta xl 18 mg prolonged-release tablets
janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 18 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient.
concerta xl 54mg prolonged release tablets
janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 54 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder in children aged 6 years of age and over when remedial measures alone prove insufficient.
durogesic dtrans 12 mcg/hr transdermal patch
janssen-cilag ltd - fentanyl - transdermal patch - 2.1 mg - phenylpiperidine derivatives - in adults: is indicated in the management of chronic intractable pain due to cancer; in the management of chronic intractable pain in children:is indicated in long term management of severe chronic pain in children receiving opioid therapy from 2 years of age.